Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEASON-AR: TAVR for Severe Native Aortic Regurgitation
NCT04864145Recruiting
- Sponsor
- Nanjing First Hospital
- Start
- May 2021
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Randomised trial in aortic regurgitation (AR) (2 arms), sponsored by Nanjing First Hospital. Primary endpoint: Clinical worsening at 12 months. Started May 2021; status: recruiting.
02
Conditions
aortic regurgitation (AR)
Beyond the preview
Go deeper on NCT04864145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04864145.